Menopause — MCQs

Menopause Indian Medical PG Practice Questions and MCQs

Question 31: Which of the following is NOT a long-term benefit of hormone replacement therapy?

A. Decreased rate of colorectal cancer
B. Decreased rate of fracture
C. Increased duration of menstrual cycles (Correct Answer)
D. Increased bone mineral density

Explanation: **Explanation:** The correct answer is **C. Increased duration of menstrual cycles.** **1. Why Option C is correct:** Menopause is physiologically defined by the permanent cessation of menstruation due to the loss of ovarian follicular activity. Hormone Replacement Therapy (HRT) is administered to alleviate vasomotor symptoms and prevent long-term complications of estrogen deficiency. While HRT (specifically cyclical progesterone) may cause "withdrawal bleeding," it does not restore or increase the duration of the natural menstrual cycle. Furthermore, the goal of HRT in postmenopausal women is symptom management, not the restoration of fertility or the menstrual cycle. **2. Why the other options are incorrect:** * **Option A (Colorectal Cancer):** Large-scale studies, including the Women’s Health Initiative (WHI), demonstrated that combined HRT (Estrogen + Progesterone) is associated with a **reduced risk** of colorectal cancer. * **Option B & D (Fractures and BMD):** Estrogen inhibits osteoclast activity. HRT is highly effective in **increasing Bone Mineral Density (BMD)** and significantly **reducing the risk of osteoporotic fractures** (hip and vertebral). This is considered one of its primary long-term benefits. **3. NEET-PG High-Yield Pearls:** * **Indications:** The primary indication for HRT is moderate-to-severe vasomotor symptoms (hot flashes). * **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60. * **Risks:** Combined HRT increases the risk of breast cancer (after 3-5 years of use), stroke, and Venous Thromboembolism (VTE). * **Uterus Rule:** If the uterus is intact, **never** give estrogen alone (unopposed estrogen) due to the high risk of endometrial hyperplasia and carcinoma; always add progesterone.

Question 32: A 58-year-old postmenopausal woman on estrogen replacement therapy complains of recent onset of spotting. A bimanual pelvic examination is unremarkable. What is the most likely diagnosis?

A. Cervical carcinoma
B. Cervical polyp
C. Dysfunctional uterine bleeding
D. Endometrial hyperplasia (Correct Answer)

Explanation: **Explanation:** The correct answer is **Endometrial hyperplasia**. **Why it is correct:** In a postmenopausal woman, the most critical concern regarding vaginal bleeding (spotting) is endometrial pathology. The patient is on **Estrogen Replacement Therapy (ERT)**. Unopposed estrogen (estrogen without progesterone) leads to continuous stimulation of the endometrial lining, causing it to become thick and disordered. This condition, known as endometrial hyperplasia, is a precursor to endometrial carcinoma. In clinical practice, any postmenopausal bleeding in a woman on ERT must be considered hyperplasia or malignancy until proven otherwise by endometrial biopsy or Transvaginal Ultrasound (TVUS). **Why other options are incorrect:** * **Cervical carcinoma:** While it can cause spotting, it usually presents with a visible lesion on the cervix or a hard, friable mass during a bimanual examination. The question states the exam is "unremarkable." * **Cervical polyp:** These are common causes of intermenstrual bleeding, but they are typically visible as smooth, red protrusions from the cervical os during a speculum examination. * **Dysfunctional uterine bleeding (DUB):** This is a diagnosis of exclusion primarily used for reproductive-age women with hormonal imbalances. In a 58-year-old, bleeding is never "dysfunctional"; it is "postmenopausal bleeding" and requires a structural/pathological investigation. **Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** Endometrial biopsy is the definitive step for postmenopausal bleeding. * **TVUS Cut-off:** An endometrial thickness (ET) of **>4 mm** in a postmenopausal woman is considered abnormal and warrants a biopsy. * **Rule of Thumb:** Always add Progesterone to Estrogen therapy in women with an intact uterus to prevent endometrial hyperplasia/cancer. * **Most common cause** of postmenopausal bleeding overall is actually **Atrophic Vaginitis/Endometritis**, but in the context of ERT, hyperplasia is the classic "textbook" answer.

Question 33: Postmenopausal hormone replacement therapy decreases the incidence of which malignancy?

A. Breast
B. Colorectal (Correct Answer)
C. Ovarian
D. Endometrial

Explanation: **Explanation:** The correct answer is **Colorectal cancer**. Large-scale clinical trials, most notably the **Women’s Health Initiative (WHI)**, have demonstrated that combined Hormone Replacement Therapy (HRT) with estrogen and progestin is associated with a **significant reduction (approximately 30-40%)** in the risk of colorectal cancer. The underlying mechanism is believed to involve estrogen’s ability to decrease the production of secondary bile acids (which are carcinogenic to the colonic mucosa) and its direct inhibitory effect on the growth of colonic epithelial cells via estrogen receptors (ER-β) in the gut. **Analysis of Incorrect Options:** * **A. Breast Cancer:** Long-term use of combined HRT (Estrogen + Progestin) is a well-known risk factor for breast cancer. Estrogen-only therapy has a lower risk but is not protective. * **C. Ovarian Cancer:** Most epidemiological studies suggest that long-term HRT use slightly **increases** the risk of ovarian cancer (particularly serous and endometrioid types). * **D. Endometrial Cancer:** Unopposed estrogen therapy in women with an intact uterus significantly increases the risk of endometrial hyperplasia and carcinoma. While adding progestin mitigates this risk, HRT does not decrease the baseline incidence. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Indication for HRT:** Moderate to severe vasomotor symptoms (hot flashes, night sweats). * **Bone Health:** HRT is highly effective in preventing **osteoporotic fractures**, but it is generally not the first-line treatment for osteoporosis alone due to other risks. * **Cardiovascular Risk:** HRT increases the risk of **Venous Thromboembolism (VTE)**, stroke, and coronary heart disease (if started late in menopause). * **The "Window of Opportunity" Hypothesis:** HRT is safest and most beneficial when started in women under 60 years of age or within 10 years of menopause onset.

Question 34: Hormone therapy in postmenopausal women is indicated for treatment of all the following conditions EXCEPT:

A. Vasomotor symptoms
B. Osteoporosis
C. Vaginal atrophy
D. Cardiovascular disease (Correct Answer)

Explanation: **Explanation:** The correct answer is **Cardiovascular disease (D)**. While estrogen was historically thought to be cardioprotective, major clinical trials like the **Women’s Health Initiative (WHI)** demonstrated that Hormone Replacement Therapy (HRT) does not prevent primary or secondary cardiovascular events. In fact, initiating HRT in older postmenopausal women may increase the risk of stroke and thromboembolism. Therefore, HRT is strictly **contraindicated** for the sole purpose of cardiovascular protection. **Analysis of other options:** * **Vasomotor symptoms (A):** This is the **most common indication** for HRT. Estrogen effectively treats "hot flashes" and night sweats by stabilizing the thermoregulatory center in the hypothalamus. * **Osteoporosis (B):** Estrogen inhibits osteoclast activity. HRT is FDA-approved for the prevention of postmenopausal osteoporosis, particularly in women at high risk of fractures who cannot tolerate other therapies. * **Vaginal atrophy (C):** Also known as Genitourinary Syndrome of Menopause (GSM), estrogen restores vaginal pH and moisture. For isolated vaginal symptoms, local (topical) estrogen is preferred over systemic therapy. **High-Yield NEET-PG Pearls:** 1. **The "Window of Opportunity" Hypothesis:** HRT is safest and most effective when started within 10 years of menopause or before age 60. 2. **Progesterone Addition:** In women with an **intact uterus**, progesterone must be added to estrogen to prevent endometrial hyperplasia and carcinoma. 3. **Contraindications:** Undiagnosed abnormal uterine bleeding, active liver disease, history of breast cancer, and active thromboembolism (DVT/PE). 4. **Drug of choice for premature ovarian insufficiency:** HRT is mandatory until the natural age of menopause (approx. 50 years) to protect bone and heart health.

Question 35: The rise in FSH during menopause is primarily attributed to which of the following physiological changes?

A. Diminished estradiol feedback
B. Decreased ovarian inhibin secretion (Correct Answer)
C. Decreased GnRH frequency
D. Increased AMH concentration

Explanation: **Explanation:** The hallmark of the menopausal transition is a significant rise in **Follicle Stimulating Hormone (FSH)**. This occurs primarily due to the depletion of the ovarian follicle pool. **Why Option B is Correct:** In a functioning ovary, **Inhibin B** (secreted by granulosa cells of antral follicles) provides a potent negative feedback signal specifically to the anterior pituitary to suppress FSH secretion. As the number of follicles declines during perimenopause and menopause, **Inhibin B levels drop first**, even before estradiol levels significantly fall. This loss of negative feedback is the earliest and most significant trigger for the rise in FSH. **Analysis of Incorrect Options:** * **Option A:** While estradiol levels eventually fall, **Inhibin B is the primary regulator of FSH**. Estradiol provides feedback to both the hypothalamus and pituitary, but its decline usually occurs later in the transition compared to the drop in Inhibin. * **Option B:** In menopause, GnRH frequency and amplitude actually **increase** (not decrease) due to the lack of negative feedback from ovarian steroids. * **Option D:** **Anti-Müllerian Hormone (AMH)** levels **decrease** (not increase) as the primordial follicle pool is exhausted. AMH is currently considered the most sensitive marker for ovarian reserve. **High-Yield Clinical Pearls for NEET-PG:** * **Earliest biochemical marker** of ovarian aging: Decreased **Inhibin B**. * **Best marker for ovarian reserve**: **AMH** (levels are cycle-independent). * **Diagnostic FSH level for menopause**: **>40 IU/L** (though >25-30 IU/L is often seen in the transition). * The **LH/FSH ratio** reverses in menopause (FSH > LH) because FSH has a slower clearance rate from the circulation.

Question 36: In a postmenopausal woman, estrogen therapy is initiated. The risk of which of the following conditions will not be increased?

A. Gallstones
B. Osteoporosis (Correct Answer)
C. Endometrial carcinoma
D. Breast cancer

Explanation: **Explanation:** The correct answer is **B. Osteoporosis**. Estrogen plays a critical role in maintaining bone mineral density (BMD) by inhibiting osteoclast activity and promoting osteoblast survival. In postmenopausal women, the decline in estrogen leads to accelerated bone resorption. Therefore, initiating Estrogen Replacement Therapy (ERT) is actually **protective** against osteoporosis and reduces the risk of fractures. It is a primary indication for Hormone Replacement Therapy (HRT), not a risk. **Analysis of Incorrect Options:** * **Gallstones (A):** Estrogen increases the saturation of cholesterol in bile and decreases gallbladder motility, leading to an increased risk of cholelithiasis (gallstones). * **Endometrial Carcinoma (C):** Unopposed estrogen causes endometrial hyperplasia. In women with an intact uterus, estrogen therapy significantly increases the risk of endometrial cancer. This is why progesterone is always added (Combined HRT) for women who have not undergone a hysterectomy. * **Breast Cancer (D):** Long-term use of combined HRT (Estrogen + Progesterone) is associated with a slightly increased risk of breast cancer, as estrogen stimulates the proliferation of mammary epithelial cells. **NEET-PG High-Yield Pearls:** 1. **Indication:** The most common indication for HRT is the management of moderate-to-severe vasomotor symptoms (hot flashes). 2. **Uterine Status:** If the uterus is present, use **Combined HRT** (E+P). If the patient has had a hysterectomy, use **ERT** (Estrogen only). 3. **Lipid Profile:** Oral estrogen increases HDL and decreases LDL (cardioprotective effect on lipids) but increases triglycerides. 4. **Contraindications:** Undiagnosed vaginal bleeding, active thromboembolism (DVT/PE), and estrogen-dependent tumors (Breast/Endometrial CA).

Question 37: Which of the following is NOT a benefit of hormone replacement therapy?

A. Prevents osteoporosis
B. Prevents breast cancer (Correct Answer)
C. Prevents colon cancer
D. Prevents stroke

Explanation: **Explanation:** The correct answer is **B (Prevents breast cancer)** because Hormone Replacement Therapy (HRT), specifically the combined estrogen-progestogen regimen, is actually associated with an **increased risk** of breast cancer when used long-term (typically >3–5 years). While estrogen-only therapy (used in women post-hysterectomy) shows a more neutral or slightly lower risk profile in some studies, HRT is never prescribed as a preventive measure for breast cancer. **Analysis of Options:** * **A. Prevents osteoporosis:** Estrogen inhibits osteoclast activity, reducing bone resorption. HRT is highly effective in maintaining bone mineral density and reducing the risk of vertebral and hip fractures in postmenopausal women. * **C. Prevents colon cancer:** Large clinical trials, including the Women’s Health Initiative (WHI), demonstrated that combined HRT significantly reduces the risk of colorectal cancer. * **D. Prevents stroke:** This is a controversial area in medical literature. While HRT can increase the risk of stroke in older women or those starting therapy late (the "Timing Hypothesis"), early initiation of HRT (near menopause) has been shown in some datasets to have a protective effect on the vasculature. However, in the context of standard NEET-PG questions, HRT is traditionally recognized for its protective effects on bones and the colon, while its link to breast cancer remains its most significant contraindication/risk. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** The primary indication for HRT is the management of moderate-to-severe vasomotor symptoms (hot flashes) and urogenital atrophy. * **The "Window of Opportunity":** HRT is safest and most beneficial when started within 10 years of menopause or before age 60. * **Endometrial Cancer:** Unopposed estrogen increases the risk of endometrial hyperplasia/cancer; therefore, progestogen must be added if the uterus is intact. * **Contraindications:** Undiagnosed vaginal bleeding, active liver disease, history of VTE, and known/suspected estrogen-dependent tumors (Breast/Endometrial CA).

Question 38: Which of the following is true about hormonal changes during menopause?

A. LH/TSH
B. Gonadotropins and estrogens (Correct Answer)
C. Estrogens and Gonadotropins
D. Estrogens and Gonadotropins

Explanation: ### Explanation **Correct Answer: B. Gonadotropins and estrogens** **1. Why the Correct Answer is Right:** The fundamental process of menopause is the **depletion of ovarian follicles**. As the number of follicles declines, there is a significant decrease in the production of **Estrogen** (specifically Estradiol/E2) and **Inhibin B**. Under normal physiological conditions, Estrogen and Inhibin provide negative feedback to the anterior pituitary and hypothalamus. With their decline, this feedback loop is lost, leading to a compensatory and dramatic **increase in Gonadotropins (FSH and LH)**. * **FSH** increases more significantly than LH due to the loss of Inhibin B and a slower clearance rate. * **Estrogen** levels fall, leading to the characteristic symptoms of menopause. **2. Why Other Options are Incorrect:** * **Option A (LH/TSH):** While LH does increase, TSH (Thyroid Stimulating Hormone) is not a primary marker of menopause. While thyroid dysfunction can mimic menopausal symptoms, it is not a diagnostic hormonal change of the climacteric. * **Options C & D:** These options list the same hormones but often in contexts implying different directions of change or are simply distractors. The diagnostic hallmark is the **inverse relationship**: High Gonadotropins (specifically FSH > 40 IU/L) and Low Estrogen. **3. NEET-PG High-Yield Clinical Pearls:** * **Gold Standard Marker:** **FSH > 40 mIU/mL** is the most sensitive and diagnostic biochemical marker for menopause. * **Estrogen Shift:** In menopause, the primary circulating estrogen changes from **Estradiol (E2)** (ovarian origin) to **Estrone (E1)** (produced via peripheral conversion of androstenedione in adipose tissue). * **Inhibin:** **Inhibin B** is the first hormone to decline during the menopausal transition (perimenopause), leading to an early rise in FSH even while cycles are still occurring. * **Androgens:** Testosterone levels also decline, but less abruptly than estrogen, often leading to a relative androgen excess (which may cause minor hirsutism).

Question 39: Levels of which of the following hormones are increased in post-menopausal women?

A. Estrogen
B. FSH (Correct Answer)
C. Progesterone
D. Cortisol

Explanation: **Explanation:** The primary physiological hallmark of menopause is the depletion of ovarian follicles. As the number of follicles declines, there is a significant decrease in the production of **Estrogen** (specifically estradiol) and **Inhibin B**. Under normal physiological conditions, Estrogen and Inhibin exert negative feedback on the anterior pituitary and hypothalamus. When these levels drop during menopause, the negative feedback loop is lost. Consequently, the pituitary gland increases the secretion of **Follicle-Stimulating Hormone (FSH)** and Luteinizing Hormone (LH) in an attempt to stimulate the non-responsive ovaries. FSH levels rise more significantly and earlier than LH, making it the most sensitive biochemical marker for menopause. **Analysis of Options:** * **A. Estrogen:** Levels decrease significantly because the ovaries no longer produce functional follicles. * **C. Progesterone:** Levels decrease because ovulation ceases, meaning no corpus luteum is formed to produce progesterone. * **D. Cortisol:** This is an adrenal hormone. While aging affects the endocrine system, cortisol levels do not characteristically increase as a direct result of menopause. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnostic Threshold:** An FSH level **>40 mIU/mL** is generally considered diagnostic of menopause in the clinical context of amenorrhea. * **Predominant Estrogen:** In post-menopausal women, **Estrone (E1)** becomes the dominant estrogen (produced via peripheral conversion of androstenedione in adipose tissue), replacing Estradiol (E2). * **LH/FSH Ratio:** In menopause, the FSH level is typically higher than the LH level (FSH > LH). * **First Sign:** The earliest biochemical change in the perimenopausal period is a decrease in **Inhibin B**, leading to a subtle rise in FSH.

Question 40: What is the major source of estrogen in postmenopausal women?

A. Peripheral conversion of androstenedione (Correct Answer)
B. Secretion from the adrenals
C. Ovarian secretion of testosterone
D. None of the above

Explanation: **Explanation:** In postmenopausal women, the ovaries cease follicular activity, leading to a significant drop in estradiol levels. The primary source of estrogen shifts from direct ovarian secretion to the **peripheral conversion of androgens.** **1. Why Option A is correct:** The major circulating estrogen in menopause is **Estrone (E1)**, which is weaker than the reproductive-age estradiol (E2). This estrone is produced via the aromatization of **androstenedione** (secreted primarily by the adrenal glands and some by the ovarian stroma). This conversion occurs in peripheral tissues, predominantly in **adipose tissue** (fat), through the enzyme aromatase. **2. Why the other options are incorrect:** * **Option B:** While the adrenal glands secrete the *precursors* (androstenedione and DHEA), they do not secrete significant amounts of active estrogen directly. * **Option C:** Although the postmenopausal ovary continues to secrete small amounts of testosterone due to LH stimulation of the stroma, this is not the primary source of systemic estrogen. Testosterone is more commonly converted to estradiol, whereas androstenedione is the primary precursor for estrone. **High-Yield Clinical Pearls for NEET-PG:** * **Estrogen Potency:** Estradiol (E2) > Estrone (E1) > Estriol (E3). * **Dominant Estrogen:** In pregnancy, it is **Estriol (E3)**; in menopause, it is **Estrone (E1)**. * **Obesity Link:** Obese postmenopausal women have higher estrone levels due to increased peripheral aromatization in adipose tissue, placing them at a higher risk for **endometrial hyperplasia and carcinoma.** * **Hormonal Profile:** Menopause is characterized by Low Estrogen, Low Inhibin, and **High FSH** (FSH >40 IU/L is diagnostic). FSH rises more significantly than LH.

Practice by Chapter

Physiology of Menopause

Practice Questions

Perimenopausal Transition

Practice Questions

Menopausal Symptoms and Management

Practice Questions

Hormone Replacement Therapy

Practice Questions

Non-hormonal Management Options

Practice Questions

Osteoporosis Prevention and Management

Practice Questions

Cardiovascular Health in Menopause

Practice Questions

Urogenital Atrophy

Practice Questions

Psychological Aspects of Menopause

Practice Questions

Premature Menopause

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?